Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation

World Journal of Surgery

Volumn 38, Issue 1, 2014, Pages 177-185

  Kong, H Y ^a   Wen, X H ^a   Huang, S Q ^a   Zhu, S M ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; PROTEIN C;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEMODYNAMICS; HUMAN; LIVER; LIVER TRANSPLANTATION; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

AMINOCAPROIC ACID; DOUBLE-BLIND METHOD; HEMODYNAMICS; HUMANS; LIVER; LIVER TRANSPLANTATION; MIDDLE AGED; PROTEIN C;

EID: 84891626965     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2282-4     Document Type: Article

References (34)

1. Aggarwal S, Kang Y, Freeman JA et al (1987) Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc 19:54-55
2. Xu ZD, Xu HT, Yuan HB et al (2012) Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. Hepatobiliary Pancreat Dis Int 11:34-39
3. García-Gil FA, Serrano MT, Fuentes-Broto L et al (2011) Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study. World J Surg 35:1598. doi: 10.1007/s00268-011-1078-7
4. Ilmakunnas M, Petäjä J, Höckerstedt K et al (2003) Activation of protein C during reperfusion in clinical liver transplantation. Transplantation 75:467-472
5. Suehiro T, Boros P, Sheiner P et al (1997) Effluent levels of thrombomodulin predict early graft function in clinical liver transplantation. Liver 17:224-229
6. Scholz T, Backman L, Mathisen O et al (1995) Activation of the plasma contact system and hemodynamic changes after graft revascularization in liver transplantation. Transplantation 60:36-40
7. Esmon CT, Taylor FB Jr, Snow TR (1991) Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 66:160-165
8. White B, Schmidt M, Murphy C et al (2000) Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110:130-134
9. Joyce DE, Gelbert L, Ciaccia A et al (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:1119-1203
10. Petäjä J, Pesonen E, Fernández JA et al (2001) Activated protein C and inflammation in human myocardium after heart surgery. Am J Hematol 67:210-212
11. Milroy SJ, Cottam S, Tan KC et al (1995) Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth 75:747-751
12. Molenaar IQ, Warnaar N, Groen H et al (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 7:185-194
13. Verstraete M (1985) Clinical application of inhibitors of fibrinolysis. Drugs 299:236-261
14. Porte RJ, Leebeek FW (2002) Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 62:2193-2211
15. Dalmau A, Sabaté A, Acosta F et al (2000) Tranexamic acid reduces red cell transfusion better than ε-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91:29-34
16. Greilich PE, Brouse CF, Rinder CS et al (2004) Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 100:225-233
17. Greilich PE, Brouse CF, Whitten CW et al (2003) Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 126:1498-1503
18. Gruber A, Griffin JH (1992) Direct detection of activated protein C in blood from human subjects. Blood 79:2340-2348
19. Massicotte L, Denault AY, Beaulieu D et al (2011) Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 91:1273-1278
20. Makwana J, Paranjape S, Goswami J (2010) Antifibrinolytics in liver surgery. Indian J Anaesth 54:489-495
21. Steib A, Gengenwin N, Freys G et al (1994) Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 73:645-648
22. Segal H, Cottam S, Potter D (1997) Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 25:683-688
23. Dalmau A, Sabaté A, Koo M et al (2004) The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transplant 10:279-284
24. Heise M, Settmacher U, Pfitzmann R et al (2003) A survival-based scoring system for initial graft function following orthotopic liver transplantation. Transpl Int 16:794-800
25. Ito T, Kiuchi T, Yamamoto H et al (2003) Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation 75:1313-1317
26. Sadaka F, O'Brien J, Migneron M et al (2011) Activated protein C in septic shock: a propensity-matched analysis. Crit Care 15:R89
27. Wagner JA, Langenfeld H, Klett L et al (2012) Activated protein C in patients with septic shock: a consecutive case series. Int J Clin Pharm 34:23-26
28. Kuriyama N, Isaji S, Hamada T et al (2010) The cytoprotective effects of addition of activated protein C into preservation solution on small-for-size grafts in rats. Liver Transplant 16:1-11
29. Keller SA, Moore CC, Clemens MG et al (2011) Activated protein C restores hepatic microcirculation during sepsis by modulating vasoregulator expression. Shock 36:361-369
30. Xia VW, Steadman RH (2005) Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transplant 11:10-18
31. Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477-14484
32. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603-16608
33. Park R, Song J, An SS (2010) Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis. Korean J Hematol 45:264-268
34. Meltzer ME, Lisman T, de Groot PG et al (2010) Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116:113-121